OBSERVER
Dr. Frank Kalkbrenner
Frank is Global Head at Boehringer Ingelheim Venture Fund (BIVF) where he has been involved in numerous investments and exits of the fund over the last years. Currently, he is on the Boards of eTheRNA, Aelin Therapeutics, RinRi Therapeutics, Acousia Therapeutics and Brainomix and prior has served as Board Member of STAT Diagnostica, Hookipa Biotech and Amal Therapeutics. Frank joined the BIVF in 2010 as Director. Before, he took over the responsibility for the R&D Licensing Department of Boehringer Ingelheim (BI) Germany in the position of Vice President starting in 2005. In addition, he built up the Biological Research unit at the German Research site in Biberach.
He joined BI in 1999 and subsequently held several positions in Pulmonary Research. Frank is a physician by training and has more than 10 years of experience in academic research with focus on pharmacology and toxicology working at the Max-Planck-Institute for Molecular Genetics (Berlin) and the Institute of Pharmacology of the Freie Universität Berlin. He studied Medicine at the Freie Universität Berlin and finished with a PhD in Pharmacology.